Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of Elpida Co-administered with Other Drugs in Healthy Volunteers
NCT03709355Phase 1Completed
- Sponsor
- Viriom Inc
- Start
- Nov 2018
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of depulfavirine in human immunodeficiency virus type 1 infection (HIV-1) (8 arms), sponsored by Viriom Inc. Primary endpoints: Plasma concentration of elsulfavirine at 42 days, Plasma concentration of VM1500A at 42 days and 6 more. Started Nov 2018; status: completed.
02
Drugs
depulfavirine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT03709355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03709355.